Printer Friendly

AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES NEW PRESIDENT KENNETH H. BURK, PH.D.

 AMERICAN BIOGENETIC SCIENCES, INC. ANNOUNCES
 NEW PRESIDENT KENNETH H. BURK, PH.D.
 NOTRE DAME, Ind., Oct. 19 /PRNewswire/ -- American Biogenetic Sciences, Inc. (ABS) (NASDAQ: MABXA) announced today that Kenneth H. Burk, Ph.D. has been appointed to the position of president, chief operating officer and a director of ABS.
 Dr. Burk will join ABS's international network from Genelabs Technologies, Inc. where his position was president of its subsidiary, BioTech Resources, Inc. (BTR). He has extensive experience as a scientist, leader and manager. In March 1991, he successfully negotiated a merger between BTR and Genelabs Technologies, Inc.
 Prior to joining BTR, Dr. Burk spent eight years with Warner Lambert. He was promoted from senior research scientist to director of research and development where he oversaw and participated in seven new product introductions and brought eight products to final development stage. Under his direction, nine products were FDA approved and released. Dr. Burk holds nine patent applications in his name.
 Mr. Alfred J. Roach, chairman and founder of ABS welcomed Dr. Burk's appointment to the team. "We are pleased to have someone of Dr. Burk's background, caliber and experience in bringing new products through the FDA and into commercial use. He brings to our company an extraordinarily wide range of scientific knowledge and leadership skills and is precisely the kind of executive we want and need to translate our scientific advances into commercial successes."
 Dr. Burk stated that "the opportunity to join the excellent staff of ABS and to work on its advanced fields of biotechnology are exciting and highly promising prospects. I look forward to being involved in the medical breakthroughs pioneered by ABS scientists and, through team effort, bringing them to commercial fruition."
 Dr. Burk's appointment comes at an exciting time for ABS, as a number of breakthrough products are in various stages of development. In the cardiovascular area, ABS has developed and received FDA approval on CADKIT, a proprietary and patented diagnostic which measure fibrinogen levels in blood plasma. An Investigational New Drug (IND) application has been filed with the FDA seeking approval to begin human clinical trials on the company's proprietary and patented imaging agent that detects clots in the heart and lungs. ABS presently has other research projects in various stages of development.
 Dr. Kenneth H. Burk is a graduate of Baylor University and Texas Tech University and earned his Ph.D. from the University of Texas Graduate School of Biomedical Sciences, Houston, Texas.
 American Biogenetic Sciences, Inc. is a biopharmaceutical company which conducts research at the University of Notre Dame, Ind., Trinity College, Dublin, Ireland and University College Galway, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease. These antibodies are produced from the company's proprietary germ-free and virtually antigen-free mouse colony.
 -0- 10/19/92
 /CONTACT: Fran Giambanco, senior vice president of American Biogenetic Sciences, 516-789-2600, or Phil Fried of The Dilenschneider Group, 212-922-0900, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic, Inc. ST: Indiana IN: MTC SU: PER


TM -- NY002 -- 1404 10/19/92 09:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1992
Words:509
Previous Article:VAN DORN ANNOUNCES 1992 THIRD QUARTER AND NINE MONTHS RESULTS
Next Article:HUMPHREY RECEIVES CONTRACT FROM LORAL AERONUTRONIC
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES APPOINTS THREE VICE PRESIDENTS
AMERICAN BIOGENETIC SCIENCES SIGNS LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
AMERICAN BIOGENETIC SCIENCES FILES WITH THE FDA TO BEGIN CLINICAL TRIALS OF BLOOD CLOT DETECTION ANTIBODY
AMERICAN BIOGENETIC SCIENCES, INC. ACQUIRES NOVEL TARGETING TECHNOLOGY FOR CANCER TREATMENT
MEDEVA PLC COMPLETES PURCHASE OF 200,000 SHARES OF AMERICAN BIOGENETIC SCIENCES, INC.
AMERICAN BIOGENETIC SCIENCES APPOINTS NATHAN B. DINCES, Ph.D EXECUTIVE VICE PRESIDENT - CORPORATE DEVELOPMENT
RIBI IMMUNOCHEM ANNOUNCES STAFF APPOINTMENTS
PHARMACEUTICAL RESOURCES, INC. ANNOUNCES APPOINTMENT OF STUART A. ROSE, PH.D. OF LEDERLE AS EXECUTIVE VP, OPERATIONS
PHARMACEUTICAL RESOURCES, INC. ANNOUNCES APPOINTMENT OF DANIEL H. GOLD, PH.D. AS VICE PRESIDENT, QUALITY ASSURANCE
American Biogenetic Sciences Inc. Appoints Stephen H. Ip, Ph.D, Executive Vice President and Chief Operating Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters